Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA

In an extraordinary step forward for the psychedelic drug research community, the US Food and Drug Administration (FDA) has just given psilocybin therapy for treatment-resistant depression a Breakthrough Therapy designation. This classification suggests the treatment has demonstrated significant potential in early clinical evidence, allowing the FDA to assist and expedite subsequent development and review processes.

.. Continue Reading Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA

Category: Science

Tags:

• Depression
• Drugs
• FDA
• Psychedelic Medicine
• Research

from New Atlas (Gizmag) https://ift.tt/2POnA1f